
Amy E. Juedes
Examiner (ID: 7188)
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1644 |
| Total Applications | 1249 |
| Issued Applications | 438 |
| Pending Applications | 166 |
| Abandoned Applications | 692 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19675954
[patent_doc_number] => 12187804
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Multivalent and multispecific 41BB-binding proteins
[patent_app_type] => utility
[patent_app_number] => 18/067484
[patent_app_country] => US
[patent_app_date] => 2022-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 50
[patent_no_of_words] => 22809
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067484
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/067484 | Multivalent and multispecific 41BB-binding proteins | Dec 15, 2022 | Issued |
Array
(
[id] => 18483652
[patent_doc_number] => 20230210953
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => USE OF DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 AND ADOPTIVE CELL THERAPIES OR BISPECIFIC T-CELL ENGAGERS TO TREAT CANCER
[patent_app_type] => utility
[patent_app_number] => 18/067535
[patent_app_country] => US
[patent_app_date] => 2022-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067535
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/067535 | USE OF DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 AND ADOPTIVE CELL THERAPIES OR BISPECIFIC T-CELL ENGAGERS TO TREAT CANCER | Dec 15, 2022 | Pending |
Array
(
[id] => 18692608
[patent_doc_number] => 20230322922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/064253
[patent_app_country] => US
[patent_app_date] => 2022-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63496
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18064253
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/064253 | HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | Dec 9, 2022 | Pending |
Array
(
[id] => 18692608
[patent_doc_number] => 20230322922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/064253
[patent_app_country] => US
[patent_app_date] => 2022-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63496
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18064253
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/064253 | HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | Dec 9, 2022 | Pending |
Array
(
[id] => 18278611
[patent_doc_number] => 20230094083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => HUMAN ANTI-GRP94 ANTIBODIES AND USES
[patent_app_type] => utility
[patent_app_number] => 18/062601
[patent_app_country] => US
[patent_app_date] => 2022-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20743
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062601
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062601 | Anti-human GRP94 antibodies and uses | Dec 6, 2022 | Issued |
Array
(
[id] => 18280961
[patent_doc_number] => 20230096433
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => Fractal Combination Therapy
[patent_app_type] => utility
[patent_app_number] => 18/062417
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11527
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062417
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062417 | Fractal Combination Therapy | Dec 5, 2022 | Pending |
Array
(
[id] => 18647913
[patent_doc_number] => 20230293692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => CELLULAR VACCINE PLATFORM AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/048230
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048230
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048230 | CELLULAR VACCINE PLATFORM AND METHODS OF USE | Oct 19, 2022 | Pending |
Array
(
[id] => 19955349
[patent_doc_number] => 12325756
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-10
[patent_title] => Use of trans-signaling approach in chimeric antigen receptors
[patent_app_type] => utility
[patent_app_number] => 18/048233
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 17
[patent_no_of_words] => 24010
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048233
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048233 | Use of trans-signaling approach in chimeric antigen receptors | Oct 19, 2022 | Issued |
Array
(
[id] => 18647913
[patent_doc_number] => 20230293692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => CELLULAR VACCINE PLATFORM AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/048230
[patent_app_country] => US
[patent_app_date] => 2022-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048230
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048230 | CELLULAR VACCINE PLATFORM AND METHODS OF USE | Oct 19, 2022 | Pending |
Array
(
[id] => 18726157
[patent_doc_number] => 20230340413
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/968410
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10688
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17968410
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/968410 | OX40L-JAGGED-1 CHIMERIC POLYPEPTIDES AND USES THEREOF | Oct 17, 2022 | Abandoned |
Array
(
[id] => 18309478
[patent_doc_number] => 20230113378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => Methods Of Treating Multiple Sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/962641
[patent_app_country] => US
[patent_app_date] => 2022-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10761
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17962641
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/962641 | Methods Of Treating Multiple Sclerosis | Oct 9, 2022 | Pending |
Array
(
[id] => 18309478
[patent_doc_number] => 20230113378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => Methods Of Treating Multiple Sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/962641
[patent_app_country] => US
[patent_app_date] => 2022-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10761
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17962641
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/962641 | Methods Of Treating Multiple Sclerosis | Oct 9, 2022 | Pending |
Array
(
[id] => 18309478
[patent_doc_number] => 20230113378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => Methods Of Treating Multiple Sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/962641
[patent_app_country] => US
[patent_app_date] => 2022-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10761
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17962641
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/962641 | Methods Of Treating Multiple Sclerosis | Oct 9, 2022 | Pending |
Array
(
[id] => 18451520
[patent_doc_number] => 20230192798
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS
[patent_app_type] => utility
[patent_app_number] => 17/938536
[patent_app_country] => US
[patent_app_date] => 2022-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75838
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938536
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/938536 | ACTIVATABLE CYTOKINE CONSTRUCTS AND COMBINATION METHODS | Oct 5, 2022 | Abandoned |
Array
(
[id] => 18523013
[patent_doc_number] => 20230233667
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => CORONAVIRUS VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/940967
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17940967
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/940967 | CORONAVIRUS VACCINE | Sep 7, 2022 | Pending |
Array
(
[id] => 18184958
[patent_doc_number] => 20230045688
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => CUSTOMMUNE: A WEB TOOL FOR DESIGNING PERSONALIZED AND POPULATION-TARGETED PEPTIDE VACCINES
[patent_app_type] => utility
[patent_app_number] => 17/901094
[patent_app_country] => US
[patent_app_date] => 2022-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6804
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17901094
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/901094 | CUSTOMMUNE: A WEB TOOL FOR DESIGNING PERSONALIZED AND POPULATION-TARGETED PEPTIDE VACCINES | Aug 31, 2022 | Pending |
Array
(
[id] => 18485185
[patent_doc_number] => 20230212512
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => REGULATORY T CELL EPITOPES
[patent_app_type] => utility
[patent_app_number] => 17/893579
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17893579
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/893579 | Regulatory T cell epitopes | Aug 22, 2022 | Issued |
Array
(
[id] => 18485185
[patent_doc_number] => 20230212512
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => REGULATORY T CELL EPITOPES
[patent_app_type] => utility
[patent_app_number] => 17/893579
[patent_app_country] => US
[patent_app_date] => 2022-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -57
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17893579
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/893579 | Regulatory T cell epitopes | Aug 22, 2022 | Issued |
Array
(
[id] => 18816073
[patent_doc_number] => 20230390412
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => COMPOSITIONS AND METHODS FOR ALLOGENEIC TRANSPLANTATION
[patent_app_type] => utility
[patent_app_number] => 17/820540
[patent_app_country] => US
[patent_app_date] => 2022-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 59721
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820540
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820540 | COMPOSITIONS AND METHODS FOR ALLOGENEIC TRANSPLANTATION | Aug 16, 2022 | Pending |
Array
(
[id] => 19594417
[patent_doc_number] => 12152247
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-26
[patent_title] => NF-
[patent_app_type] => utility
[patent_app_number] => 17/871680
[patent_app_country] => US
[patent_app_date] => 2022-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 19
[patent_no_of_words] => 9522
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17871680
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/871680 | NF- | Jul 21, 2022 | Issued |